These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 14706214)

  • 1. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
    Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
    J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease?
    Kupersmith MJ
    J Neurol Sci; 2004 Feb; 217(2):123-4. PubMed ID: 14706212
    [No Abstract]   [Full Text] [Related]  

  • 4. Cigarette Smoking and Activities of Daily Living in Ocular Myasthenia Gravis.
    Gratton SM; Herro AM; Feuer WJ; Lam BL
    J Neuroophthalmol; 2016 Mar; 36(1):37-40. PubMed ID: 26457691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.
    Kupersmith MJ
    J Neurol; 2009 Aug; 256(8):1314-20. PubMed ID: 19377863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Childhood myasthenia gravis: clinical features and outcomes.
    Sri-udomkajorn S; Panichai P; Liumsuwan S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to treatment in pediatric ocular myasthenia gravis.
    Xu L; Castro D; Reisch JS; Iannaccone ST
    Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment.
    Kupersmith MJ; Ying G
    Br J Ophthalmol; 2005 Oct; 89(10):1330-4. PubMed ID: 16170126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
    Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
    Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual and systemic outcomes in pediatric ocular myasthenia gravis.
    Pineles SL; Avery RA; Moss HE; Finkel R; Blinman T; Kaiser L; Liu GT
    Am J Ophthalmol; 2010 Oct; 150(4):453-459.e3. PubMed ID: 20678749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis.
    Zach H; Cetin H; Hilger E; Paul A; Wuschitz B; Jung R; Auff E; Zimprich F
    Eur J Neurol; 2013 Apr; 20(4):708-13. PubMed ID: 23279780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular myasthenia gravis - How effective is low dose prednisone long term?
    Verma R; Wolfe GI; Kupersmith MJ
    J Neurol Sci; 2021 Jan; 420():117274. PubMed ID: 33360170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of prednisone for the treatment of ocular myasthenia (EPITOME): A randomized, controlled trial.
    Benatar M; Mcdermott MP; Sanders DB; Wolfe GI; Barohn RJ; Nowak RJ; Hehir M; Juel V; Katzberg H; Tawil R;
    Muscle Nerve; 2016 Mar; 53(3):363-9. PubMed ID: 26179124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis.
    de Meel RHP; Tannemaat MR; Verschuuren JJGM
    Neuromuscul Disord; 2019 Sep; 29(9):664-670. PubMed ID: 31488385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ocular myasthenia: clinical course and strategies for treatment].
    Marzo ME; Pérez López-Fraile I; Capablo JL; Ara JR; Usón M
    Rev Neurol; 1998 Mar; 26(151):398-400. PubMed ID: 9585951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The natural history and ophthalmic involvement in childhood myasthenia gravis at the hospital for sick children.
    Mullaney P; Vajsar J; Smith R; Buncic JR
    Ophthalmology; 2000 Mar; 107(3):504-10. PubMed ID: 10711889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolate mofetil for ocular myasthenia.
    Chan JW
    J Neurol; 2008 Apr; 255(4):510-3. PubMed ID: 18299952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
    Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
    Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.